Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial
Lancet 373:732-738, Goodman,A.D.,et al, 2009
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Quantitative Assessment of Sustained-Release 4-Aminopyridine for Symptomatic Treatment of Multiple Sclerosis
Neurol 48:817-821, Schwid,S.R.,et al, 1997
4-Aminopyridine in the Treatment of Patients with Multiple Sclerosis:Long-term Efficacy and Safety
Arch Neurol 51:292-296, Polman,C.H.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Effect of 4-Aminopyridine on Clinical Signs in Multiple Sclerosis
Ann Neurol 32:123-130, vanDiemen,H.A.M.,et al, 1992
4-Aminopyridine in Multiple Sclerosis:Prolonged Administration
Neurol 41:1344-1348, Stefoski,D.,et al, 1991
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977